CryoPort (NASDAQ:CYRX) Director Daniel Hancock Sells 74,379 Shares of Company Stock

CryoPort, Inc. (NASDAQ:CYRX) Director Daniel Hancock sold 74,379 shares of CryoPort stock in a transaction on Monday, November 9th. The stock was sold at an average price of $20.21, for a total transaction of $1,503,199.59. Following the transaction, the director owned 69,052 shares in the company, valued at approximately $1,395,540.92. This trade represents a 51.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

CryoPort Stock Down 2.2%

Shares of CryoPort stock opened at $20.10 on Friday. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -20.72 and a beta of 1.89. CryoPort, Inc. has a twelve month low of $7.61 and a twelve month high of $21.78. The company’s fifty day moving average is $17.35 and its 200 day moving average is $13.65.

CryoPort (NASDAQ:CYRX) last announced its earnings results on Thursday, November 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The company had revenue of $50.22 million for the quarter, compared to the consensus estimate of $48.66 million. CryoPort had a negative return on equity of 8.28% and a negative net margin of 21.46%. As a group, equities analysts anticipate that CryoPort, Inc. will post -0.88 earnings per share for the current fiscal year.

Institutional Trading of CryoPort

Institutional investors have recently bought and sold shares of the company. State of Alaska Department of Revenue acquired a new stake in CryoPort during the 3rd quarter worth about $40,000. State of Wyoming acquired a new stake in CryoPort during the third quarter worth approximately $81,000. Highland Investment Advisors LLC bought a new stake in CryoPort in the second quarter worth approximately $306,000. Counterpoint Mutual Funds LLC bought a new stake in CryoPort in the third quarter worth approximately $324,000. Finally, Diversified Trust Co increased its holdings in CryoPort by 3.4% in the third quarter. Diversified Trust Co now owns 19,769 shares of the company’s stock worth $344,000 after purchasing an additional 657 shares in the last quarter. Institutional investors own 92.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CYRX. Guggenheim raised their price objective on CryoPort from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Needham & Company LLC upped their target price on CryoPort from $19.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 6th. Weiss Ratings upgraded CryoPort from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, October 8th. Piper Sandler raised shares of CryoPort to a “buy” rating in a research report on Tuesday, October 13th. Finally, Robert W. Baird set a $26.00 price target on shares of CryoPort in a report on Tuesday, October 13th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $21.69.

About CryoPort

Cryoport, Inc. provides temperature-controlled supply chain services for the life sciences industry. Its offerings support the development and commercial distribution of cell and gene therapies, biologics, reproductive medicine products and other temperature-sensitive materials. The company’s services include specialized shipping systems and packaging, transportation management, cryogenic storage, shipment monitoring and logistics support. These solutions are designed to help customers maintain required conditions and manage the handling of sensitive materials across clinical and commercial supply chains.